Full Event Guide
What will you learn in 3 days?
- Leverage DDR inhibitor, radiation and chemotherapy combinations and optimize therapeutic efficacy
- Delve into DDR biology, genotypes & biomarker strategy with models to inform patient selection & expand indications
- Gain a birds-eye-view of the DDR landscape and future outlooks with industry leaders such as AstraZeneca, Bayer, Merck & Tesaro: a GSK Company